一周医药速览（11.17-11.21）

Group 1: Sanofi Pharmaceutical - Sanofi Pharmaceutical announced plans to spin off its subsidiary Mandi Holdings for independent listing on the Hong Kong Stock Exchange [1] - The proposed spin-off will involve a distribution of Mandi shares to existing shareholders based on their holdings in Sanofi [1] - Mandi Holdings is registered in the Cayman Islands and is currently owned by Sanofi and other entities, with Sanofi holding approximately 87.16% [1] Group 2: Yaoshi Bang - Yaoshi Bang reported a 15% year-on-year revenue growth for the third quarter ending September 30, 2025, surpassing the growth rate of the first half of 2025 compared to the same period in 2024 [2] - The company's self-owned brand business saw a transaction volume increase of over 350% year-on-year, contributing significantly to overall growth [2] - The strategic focus on self-owned brand products aims to meet diverse market demands and enhance profitability [2] Group 3: SenseTime Medical - SenseTime Medical completed a new round of strategic financing amounting to several hundred million yuan, with notable investors including Lenovo Ventures and others [3] - This financing reflects strong market recognition of SenseTime Medical's technological capabilities and growth potential [3] - The company is also initiating Series A financing with a post-investment valuation exceeding 3 billion yuan [3] Group 4: National Medical Products Administration - The National Medical Products Administration released a document outlining 24 reform measures to enhance the quality and safety of cosmetics [4] - The reforms aim to encourage innovation, optimize registration management, and strengthen risk prevention across the cosmetics industry [4] - By 2030, the goal is to have a more robust regulatory framework and improved safety standards in the cosmetics sector [4] Group 5: Hanyu Pharmaceutical - Hanyu Pharmaceutical announced the appointment of former senior executive Shen Yaping from Heng Rui Pharmaceutical as the new Executive President [5][6] - Shen Yaping has extensive experience in international business development and regulatory affairs in the pharmaceutical industry [6] - The company aims to adapt to a complex market environment through this strategic leadership change [6] Group 6: Meili Tianyuan Medical Health - Meili Tianyuan Medical Health plans to acquire 100% equity of several companies for a total consideration of 40 million yuan [7] - The acquisition will expand the company's direct-operated stores by 19, including two medical beauty stores and 17 lifestyle beauty stores [7] - This move is expected to enhance the company's revenue and strengthen its market presence in key cities in the Greater Bay Area [7]